Early Detection of Central Visual Function Decline in Cone-RodDystrophy by the use of Macular Focal Cone Electroretinogram by Resta, Giovanni et al.
Clinical and Epidemiologic Research
Early Detection of Central Visual Function Decline in
Cone–Rod Dystrophy by the Use of Macular Focal Cone
Electroretinogram
Lucia Galli-Resta,1 Marco Piccardi,2 Lucia Ziccardi,3 Antonello Fadda,4 Angelo Minnella,2
Dario Marangoni,2 Giorgio Placidi,2 Giovanni Resta,5 and Benedetto Falsini2
1Istituto di Neuroscienze Consiglio Nazionale delle Ricerche (CNR), Pisa, Italy
2Institute of Ophthalmology, Policlinico Gemelli, Catholic University, Rome, Italy
3Bietti Foundation, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy
4Tecnologie e Salute, Istituto Superiore di Sanita`, Rome, Italy
5Istituto di Informatica e Telematica CNR, Pisa, Italy
Correspondence: Benedetto Falsini,
Istituto di Oftalmologia, Universita`
Cattolica del Sacro Cuore, Lgo F. Vito
1, 00168 Rome, Italy;
bfalsini@rm.unicatt.it.
LG-R and BF contributed equally to
the work presented here and should
therefore be regarded as equivalent
authors.
Submitted: June 26, 2013
Accepted: August 20, 2013
Citation: Galli-Resta L, Piccardi M,
Ziccardi L, et al. Early detection of
central visual function decline in
cone–rod dystrophy by the use of
macular focal cone electroretinogram.
Invest Ophthalmol Vis Sci.
2013;54:6560–6569. DOI:10.1167/
iovs.13-12676
PURPOSE. To evaluate macular focal cone ERG (fERG) as a tool for reliable and early detection
of central retinal function decay in cone–rod dystrophy (CRD).
METHODS. A retrospective study of the time course of fERG amplitude and its relation to visual
acuity alterations was performed in 47 CRD patients followed yearly for 6.0 6 3.1 years.
Macular focal cone ERG was evoked by a flickering uniform red field overlaying the central
188 of visual field.
RESULTS. Macular focal cone ERG follow-up allowed a clear-cut identification of CRD patients
as stationary or progressive, in agreement with visual acuity follow-up. In all progressive
patients, fERG declined whenever visual acuity declined, and—in 50% of the cases—fERG loss
anticipated acuity loss of several years.
CONCLUSIONS. Macular focal cone ERG represents a sensitive assay to detect, categorize, and
follow the progression of central retinal dysfunction in CRD. Its use as a diagnostic tool in
CRD may help anticipate, for an individual patient, the likelihood and rate of further disease
progression before visual acuity loss has occurred.
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Cone–rod dystrophies (CRDs) are a group of inheritedretinal disorders representing a major cause of blindness in
children and young adults.1,2 Cone–rod dystrophies are
characterized by early decline of visual acuity and loss of
sensitivity in the central visual field, photosensitivity, and color
vision deficits, later followed by progressive loss in peripheral
vision.1,3 During the course of the disease, pigmentary changes
of the macula and a midperipheral pigmentation become
apparent. Full-field ERG shows abnormalities of both cone and
rod responses, with cone responses typically more severely and
more precociously affected than rod responses.3–8
The natural history of CRDs is known to be variable,
reflecting the clinical and genetic heterogeneity of this group
of diseases. The disease can be stationary or progressive,
with variable age of visual decay onset. Landmark studies
employed ERG, dark-adaptometry visual acuity loss, fundus
imaging, and modified perimetric techniques to describe the
different subtypes of functional CRD phenotypes.3–8,9 These
phenotypes are now being matched with the emerging
molecular genetic classification of the disease.2,5,10–13
Yet, at present, few clinical studies have longitudinally
evaluated the rate of retinal function loss in progressive CRD
forms,5,12,14 and reliable diagnostic tools for an early
identification of the patient risk of decay are still under
investigation.10,15 To contribute to this effort, we present
here a retrospective longitudinal study testing the clinical
effectiveness of the macular focal cone ERG (fERG) recorded
over the central 188 of visual field for monitoring, phenotyp-
ing, and anticipating CRD progression in the central retina.
METHODS
Patients
This is a retrospective study based on the database of CRD
patients clinically followed at the Visual Electrophysiology
Service of the Institute of Ophthalmology at the Universita`
Cattolica del Sacro Cuore in Rome, Italy. Patients had sought
consultation because of visual symptoms. Following the first
visit, they were invited to adhere to the Institutional
schedule of one examination per year. The actual date of
each visit was established by an independent administrative
office. All patients had a diagnosis of CRD based on history,
clinical findings, and ERG abnormalities. All patients gave
informed consent to participate to the study, which adhered
to the tenets of the Declaration of Helsinki and was
approved by the Institutional Review Board.
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Inclusion Criteria
The long-term changes of fERG in CRD were evaluated in a
cohort of 47 patients with a follow-up ‡2.5 years (Table) who
met the following inclusion criteria: (1) typical CRD with a
cone–rod pattern of retinal dysfunction (Fig. 1), as determined
by International Society for Clinical Electrophysiology of Vision
(ISCEV) standard Ganzfeld ERG,16 dark-adapted Tuebinger
perimetry, and classic fundus appearance; (2) inheritance
pattern unequivocally determined by a detailed family and
medical history; (3) no or minimal ocular media opacities; (4)
absence of nystagmus; (5) foveal fixation or preferred retinal
locus for fixation within 38 of the fovea and stable throughout
the follow-up; (6) no concomitant ocular, visual, or systemic
diseases; and (7) baseline age ‡9 years, as tests of younger
children proved unreliable. The data set analyzed derived from
262 recording sessions performed from 1999 to 2012 under
the same test conditions.
TABLE. Patient Cohort
Patient
No.
Follow-up,
y Visits Sex Inheritance
Age,
y
fERG,
lV*
Baseline Values
BCVA (Decimal)*
% of Normal Value
Rod ERG
b-Wave*
Cone ERG
b-Wave*
01 11.5 5 M AR 48 0.30 1 80 60
02 6.2 8 M AR 15 1.35 1 90 75
03 5.1 3 F AR 30 0.6 0.05 60 45
04 6.2 4 M AR 11 0.27 0.8 60 20
05 5 5 F S 49 1.56 1 80 35
06 8.7 5 F AR 59 0.34 0.9 70 65
07 3.2 5 F AR 10 1.96 0.9 80 75
08 10 11 F AR 20 0.65 0.45 70 35
09 4.1 5 M S 13 0.79 0.5 60 25
10 5.4 5 F AR 21 1.62 1 70 35
11 7.4 9 F AR 11 0.35 0.2 75 25
12 4.7 5 F AR 9 1.08 0.5 60 30
13 3.2 5 M AR 28 0.26 0.6 80 45
14 7.4 9 F AR 11 0.7 0.3 85 40
15 5.4 7 M AR 10 1.75 0.2 80 30
16 3.8 6 F AR 9 0.88 0.4 60 20
17 5.3 6 F AR 41 0.73 0.3 80 20
18 8 9 F AR 27 0.63 0.1 60 35
19 7.2 11 F AR 42 0.33 0.2 60 25
20 8.6 6 M AR 19 1.21 0.6 80 40
21 4 4 M AR 13 0.32 0.3 90 30
22 9.8 14 M S 11 0.13 0.9 90 50
23 2.7 4 M AR 44 1.04 0.2 85 45
24 2.9 3 M AR 11 1.65 0.65 85 25
25 12.6 20 F AR 9 0.67 0.2 65 10
26 10.2 13 F AR 36 0.52 0.3 50 10
27 5.9 5 F AR 13 1.48 0.1 40 15
28 11.8 7 M AR 25 0.29 0.4 80 8
29 9.4 3 F AD 58 0.24 0.3 85 15
30 2.7 3 M AR 36 0.64 0.05 50 25
31 3.4 5 F AR 24 1.2 1 80 45
32 3 5 M AR 10 1.27 0.9 80 55
33 10.2 9 F S 27 1.22 0.4 95 25
34 5.8 6 M AR 18 0.26 0.3 65 15
35 2.6 2 F AR 20 1.61 0.5 75 30
36 10.4 2 M AR 45 0.67 1 80 60
37 2.4 2 M AR 39 2.125 1 80 40
38 2.9 2 M AR 46 1.88 0.2 85 55
39 3 3 M AR 12 1.2 1 85 25
40 3 3 F AR 40 0.68 1 75 15
41 6.6 2 F AR 22 2.54 0.2 65 25
42 11.3 2 F AD 46 0.15 0.1 60 15
43 2.8 2 F AR 36 0.44 0.2 85 35
44 4.6 2 F AR 33 0.81 0.1 60 20
45 11.6 2 M AR 49 2.2 0.3 65 15
46 2.6 2 M AR 57 1.13 0.3 85 25
47 2.5 6 F AR 11 1.36 0.8 65 15
AD, autosomal dominant; S, sporadic; AR, autosomal recessive.
* Average between the two eyes.
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Measures of Ocular Function and ERG
A full general and ophthalmologic examination (including
detailed family history, anterior segment biomicroscopy, best
corrected Snellen visual acuity, direct and indirect ophthal-
moscopy, and IOP measurement) was performed on each
patient at baseline and on several consecutive visits.
Macular focal cone ERG (fERG) was recorded from the
central 188 region using a flickering uniform red field
superimposed on a constant equiluminant steady adapting
background minimizing stray-light modulation.17,18 The stimu-
lus was generated by a circular array of eight red light-emitting
diodes (LEDs) (660 nm; 93 cd/m2) presented on the rear of a
Ganzfeld bowl. A diffusing filter in front of the LED array made
it appear as a circle of uniform red light. Macular focal cone
ERGs were recorded in response to the 41-Hz sinusoidal 95%
luminance modulation of the central red field. Patients fixated
monocularly a 0.258 central fixation mark, under the constant
FIGURE 1. Representative Ganzfeld ERGs and fundus images of the CRD patients in the cohort. (A) Examples of ERG recordings according to ISCEV
standard in a normal subject (left) and a representative CRD patient (patient No. 13 in the Table). From top to bottom: Rod response, mixed rod and
cone response, single-flash cone response, 31-Hz flicker response. (Note that the patient’s ERG shows a substantial loss of single-flash and flicker
response, whereas rod and mixed responses are relatively spared, compared with the control ERG.) (B, C) Baseline fundus images from patient No.
31 (B), illustrating an early phase of the disease, and patient No. 30 (C), illustrating a late phase. Left: Infrared images. Right: Fundus
autofluorescence.
FIGURE 2. Reduced fERG amplitudes in CRD patients. (A) Baseline fERG values in normal control (Ctrl) and in the CRD patients of the study cohort.
fERG values are average between the two eyes. Control values are from a cohort of 28 age-matched normal subjects recorded in the same conditions
as the CRD patients. Average Ctrl fERG 2.33 6 0.46 (N¼ 28), CRD baseline fERG 0.96 6 0.61 (N¼ 47). The difference in fERG values is statistically
significant (P < 104 Mann-Whitney test). (B) Example of fERG recordings obtained at baseline and 4 years later from three CRD patients.
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monitoring of an external observer. Pupils were pharmacolog-
ically (1% tropicamide and 2.5% phenylephrine hydrochloride)
dilated to a diameter ‡8 mm, and all subjects underwent a 20-
minute preadaptation period to the stimulus mean luminance.
Macular focal cone ERG was recorded by means of an Ag-AgCl
0.9-cm diameter skin electrode taped on the skin of the lower
eyelid, after coating the electrode surface with saline electro-
conductive gel. A similar electrode on the lower eyelid of the
contralateral patched eye was used as reference.
For each recording, fERG signals were amplified (100,000-
fold), bandpass filtered (1–100 Hz; 6 dB/octave), and averaged
(12-bit resolution, 2-kHz sampling rate, 1200–1600 repetitions
in 6–8 blocks). Off-line discrete Fourier analysis quantified the
amplitude of the response first harmonic at 41 Hz. Two
recordings (6–8 blocks each) were commonly acquired on
each visit. In accordance with previous studies,19 noise level
was computed as the signal Fourier component at 45 Hz, a
frequency different but very close (10% difference) to the real
signal modulation frequency.
In this retrospective study, we could not rely on systematic
recordings documenting short-term variability. Therefore, to
determine a priori cutoff for repeatability of fERG recording in
individual patients, we used within-session variability. This
choice has the limitation of excluding some potential sources
of variation such as pupil size or electrode placement.
However, it has the advantage of being unaffected by the
rapid decrease of fERG with time in fast-declining patients.
Data Analysis
Macular focal cone ERG decline over time was fitted with a
simple exponential decay model in agreement with previous
studies.10,14 Since fERG amplitude distributions were skewed,
individual fERG values were transformed into logarithms (base
10), followed by linear regression analysis of logfERG
amplitude versus time. Linear regression analysis of individual
patient fERG data showed no ‘‘ceiling’’ or ‘‘floor’’ effects (not
shown), and thus no censoring was performed.20,21 Between-
group difference for fast- and slow-decaying patient sets was
evaluated by comparing the distributions of decay rates
obtained by linear fitting of individual curves in either set.
Average decay rate within either set was estimated by global
linear fitting, a linear model that allows individual intercepts to
vary with patients and optimizes the fit with a single decay-rate
parameter (slope) common for all individual patient curves.
The advantage of this model is the simultaneous use of the
entire data set to determine a common average decay without
external assumptions about weighting factors and modali-
ties.20,21
Relationship Between Visual Acuity and fERG
Changes
Best-corrected visual acuity (BCVA) values were expressed as
log values of the minimum angle of resolution (MAR), in
accordance with previous studies. Changes in BCVA with time
were expressed as DlogMAR (logMAR[time1]  logMAR
[time2], with time2 subsequent to time1), to represent visual
acuity losses with negative values. To study the relationship
between fERG and VA variation, we considered every pair of
visits where both fERG and VA were recorded in a patient, we
computed DlogMAR and Dlog fERG (log fERG[time2]  log
fERG[time1]) for each eye, then we plotted together data
obtained from all patients.
A Posteriori Receiver–Operator Characteristic
(ROC) Curves for fERG Test Decay Detection and
Bootstrap Analysis
This computation was performed in four steps. First, we
obtained cumulative probability curves for fERG percentage
loss between visits for each set of patients. Second, we
computed specificity and sensitivity curves—where specificity
is the likelihood of correct identification of stationary patients,
and sensitivity is the likelihood of correct identification of
decaying patients (whether fast or slow decaying). Third, we
computed the corresponding ROC curves, which plot sensi-
tivity as a function of (1-specificity). Fourth, we used bootstrap
FIGURE 3. Macular focal cone ERG follow-up shows two distinct sets of stationary CRD patients. (A) fERG time courses of high-amplitude fERG
stationary patients (fERG ‡1 lV). (B) Examples of fERG time courses for low-amplitude stationary patients (fERG 0.5 lV). In each panel, fERG is
plotted on a logarithmic scale. Each symbol corresponds to a patient.
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analysis to obtain the distribution of values for the area under
the ROC curve, a standard means to evaluate the accuracy of a
test. Specifically, for each patient and interval of time, we
selected all the pairs of measures that were separated in time
by the set interval. Chosen time intervals were 1, 2, and 3
years, each with 0.5-year tolerance (e.g., measures separated
from 0.5 to 1.5 years were considered for the 1-year interval).
For each pair of measures, we computed the difference
between the more recent and the older measure and expressed
it as the percentage of the latter. Pooling together measures
from all patients in each category, we determined the
corresponding cumulative probability curves. As expected,
the cumulative probability curves for stationary patients did
not significantly change with the time interval (not shown),
and high and low stationary-patient curves coincided (not
shown). From these probability curves, we computed sensi-
tivity and specificity for discriminating decaying patients from
stationary patients as a function of fERG threshold and built the
corresponding ROC curves. For bootstrap analysis,22 we
focused on the data sets collecting fERG differences after 1
and 3 years. For each data set, we ran 10,000 bootstrap
simulations. In bootstrap simulations, N data are extracted
from the data set (where N is the total number of measures in
the data set) allowing repetition, so that each measure can be
extracted multiple times in each simulation
Statistical Analysis
Data were analyzed with Origin 8.5 (OriginLab Corporation,
Northampton, MA) and GraphPad Prism 6.0 (GraphPad
Software, Inc., La Jolla, CA). Unless otherwise specified, data
are presented as mean 6 standard deviation. Differences
between two groups were compared using Student’s t-test, or
Mann-Whitney rank test in case of non-normal distributions.
Differences in baseline ages across groups were compared
using Kruskal-Wallis nonparametric test. Normality test was
performed using the D’Agostino-Pearson omnibus K2 test. For
linear regression, residuals were analyzed by the D’Agostino-
Pearson omnibus K2 normality test, and run tests. Fit results
were considered only when the fit converged and P < 0.01.
Following established convention, the quality of fit was
recorded as adjusted coefficient of determination (adjusted
R2 [Adj R2]) and P value). Values obtained by best fitted
regression lines are reported together with their 95%
confidence interval (CI).
RESULTS
The study cohort consisted of 47 CRD patients (21 males and
27 females), with a total of 262 visits (Table). The average
FIGURE 4. Two distinct clusters of fERG decay rates in progressive CRD forms. (A) Fast fERG decay was observed in nine patients, with an average
loss of 34% fERG amplitude per year (95% CI, 28.4%39.3%; global linear fit of logfERG data). Data are plotted on a logarithmic scale. Each symbol
corresponds to a patient. Gray lines indicate the individual fit lines. (B) Slow fERG decay was observed in 13 patients, with an average loss of8.6%
fERG amplitude per year (95% CI, 7.1%–10.1%). Data are plotted on a logarithmic scale. Each symbol corresponds to a patient. Gray lines indicate
the individual fit lines. (C) Fast- and slow-decaying fERG curves are replotted by shifting them along the abscissa in order to align each curve in
either set along one fit line. The curve envelopes thus obtained illustrate the difference between the two decay behaviors over the years. Notice that
none of the curves is normalized.
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follow-up was 6.1 6 3.1 years (range, 2.5–12.6 years) with an
average of 1.0 6 0.5 visit per year. Age at baseline was 27.1 6
15.7 years. Minimum age at baseline was 9 years, maximum age
at final follow-up was 67 years. Unless otherwise specified, we
averaged visual measures between the two eyes for the
analysis.
fERG in CRD Patients
Most CRD patients in the cohort had baseline fERG responses
smaller than those observed in normal individuals of similar age
(Fig. 2A; control, N¼28; CRD, N¼47; P < 0.05 Mann-Whitney
rank test). All CRD responses, however, remained well above
noise level (average noise level at baseline, 0.03 6 0.05 lV; N¼
47). In the follow-up, fERG responses remained stationary for
approximately half of the patients, while the remaining half
experienced significant fERG reduction with time, as exempli-
fied by the recordings from three patients in Figure 2B.
fERG Repeatability
To obtain preliminary cutoff criteria to discriminate stationary
and progressive time courses, we analyzed fERG within-visit
variability (see Methods section). For each patient, we
compared the amplitude of the two fERG recordings obtained
at baseline, expressing their difference as the percentage of
their average, and used the fifth and 95th percentiles of the
difference distribution across patients as cutoff limits for
stationary fERG. Such limits were56.9% and 52%, respective-
ly. Therefore, we considered patients as declining when their
fERG amplitude lost more than 56.9% of the baseline value
during follow-up, improving if the fERG amplitude increased
by more than 52% of the baseline value, and stationary if their
fERG changes remained within the cutoff limits. According to
these criteria, 25 of the 47 cohort patients had a stationary
fERG follow-up, while the remaining 22 patients showed an
fERG declining with time. Follow-up duration did not
significantly differ between stationary and decaying patients
(Student’s t-test; P < 0.05).
Stationary fERG Patients
In 25 of the 47 patients, fERG amplitude remained stationary
during the follow-up. With rare occasional exceptions, 12
patients had fERG constantly ‡1 lV (Fig. 3A) and 13 had fERG
0.5 lV (Fig. 3B). Only 11 of the 131 measures obtained from
stationary fERG patients fell within the 0.5- to 1-lV range.
Baseline age was not significantly different between high (fERG
>1 lV) and low (fERG <0.5 lV) stationary patients (high
stationary, 29 6 17 years; low stationary, 31 6 19 years; P ¼
0.6 Mann-Whitney rank test).
Decaying fERG Patients
In 22 of the 47 patients, fERG amplitude declined with time.
Macular focal cone ERG decline was either fast (Fig. 4A, nine
patients) or slow (Fig. 4B, 13 patients). Global linear fitting
gave an average annual fERG loss of 34.0% for fast-decaying
patients (95% CI, 28.4%–39.3%; N¼ 9 patients, df¼ 20, Adj R2
¼ 0.79), and 8.6% for slowly decaying patients (95% CI, 7.1%–
10.1%; N ¼ 13 patients, df ¼ 56, Adj R2 ¼ 0.91). This 3-fold
FIGURE 5. Macular focal cone ERG and BCVA follow-up in patients with stationary fERG. (A, B) fERG follow-up values plotted in log unit changes
from baseline for patients with high (A) and low (B) stationary fERG. Time courses are for individual eyes. (C, D) BCVA follow-up values for
individual eyes from patients with high (C) and low (D) stationary fERG. BCVA is plotted as log unit changes from baseline in the MAR.
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difference in decay rate was statistically significant (Mann-
Whitney rank test, P < 0.001; see Methods section).
The fast- and slow-decaying curve sets spanned the same
voltage range—from 1 to 2 lV to below 0.5 lV, suggesting that
fast- and slow-decaying patients undergo the same functional
decline, but with two quite different time courses. This finding
is emphasized in Figure 4C, where the curves in each set are
shifted along the abscissa to make their fit lines converge onto
a single line, thus modeling the expected time span for overall
decline in either set. Baseline age was not significantly different
between fast- and slow-progressing patients (fast decaying, 25
6 13 years; slow decaying, 22 6 12 years; P ¼ 0.6; Student’s
t-test), nor in general between any pair of patient groups
identified by fERG follow-up (Kruskal-Wallis test; P ¼ 0.44).
fERG and Visual Acuity Loss
To understand how the classification in stationary and
decaying CRD patients according to fERG follow-up is related
to the outcome of more established clinical tests, we compared
the time courses of fERG and BCVA.
Long-term BCVA follow-up was available for 18 patients
with stationary fERG and 19 patients with decaying fERG, and
the two groups had very similar BCVA follow-up duration (5.1
6 2.8 years for fERG-stationary patients and 5.5 6 2.9 years for
fERG-decaying patients, P ¼ 0.67 Student’s t-test). The fERG
and BCVA time courses—expressed as relative changes from
baseline—are illustrated in Figure 5 for patients with stationary
FIGURE 6. Macular focal cone ERG and BCVA follow-up in patients with decaying fERG. (A, B) fERG follow-up plotted in log unit changes from
baseline for patients with fast (A) and slow (B) decaying fERG. Time courses are for individual eyes. (C, D) BCVA follow-up for individual eyes from
patients with fast (C) and slow (D) decaying fERG. BCVA is plotted in log unit changes from baseline in the MAR.
FIGURE 7. Macular focal cone ERG decline always accompanies and
often anticipates BCVA decline. Intervisit variation in fERG as a
function of BCVA variation from all patients with decaying fERG. BCVA
is plotted as logMAR. Both fERG and BCVA variations are plotted as
log unit loss between the first and the second of the two visits, which
are compared.
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fERG and in Figure 6 for fERG-decaying patients. On the
average, patients with stationary fERG (Fig. 5) experienced
little if any BCVA loss with time, with an average maximum
decay of 13% (0.06 6 0.07 log units; N ¼ 36 eyes) in their
minimum angle of resolution (MAR). On the contrary, patients
with decaying fERG (Fig. 6) had an average loss in MAR with
time of 55% (0.35 6 0.33 log units; N ¼ 38 eyes), and all
experienced BCVA decline with time (Fig. 6), excluding two
patients whose baseline acuity was already below 0.1 decimals.
Taken together, these data show that fERG follow-up discrim-
inates stationary and progressive CRD forms in close agree-
ment with the discrimination derived from BCVA follow-up.
We next analyzed how fERG losses related to BCVA losses in
decaying patients. Considering individual eye measures, we
found that all BCVA losses (55/55; N ¼ 38 eyes; 19 patients)
corresponded to a simultaneous fERG loss in the same eye (Fig.
7). However, fERG losses could occur without BCVA loss; in
65% of the cases (36/55) a BCVA loss was also preceded by a
fERG loss, which was detected while the patient’s acuity was
still stable. These events are exemplified for individual cases in
Figure 8.
These results were quantified in terms of BCVA survival
probability following fERG loss in decaying patients (Fig. 9).
Specifically, for all decaying patients, we computed the time
between the first fERG loss from baseline and the first BCVA
loss (upper curve), as well as the time between the first fERG
loss and the last visit where the BCVA was still at baseline
(lower curve), reasoning that the two curves represent an
upper and a lower bound, respectively, for BCVA survival
probability. In all decaying patients, we found that when fERG
declines, BCVA is doomed to do so, although in half of the
patients, BCVA can survive several years after the first fERG loss
(Fig. 9).
A Posteriori ROC Curves for fERG Decay Detection
The analysis hereto described began by setting a priori criteria
to discriminate stationary and decaying fERG time-courses. A
posteriori, more realistic cutoff criteria can be determined by
knowing the behavior of stationary and decaying fERG time
curves. Specifically, one can use the data set to compute the
likelihood of a correct identification of a decaying patient
(sensitivity), and the corresponding risk of mistaking a
stationary patient for a progressing one (1-specificity), as a
function of fERG decay cutoff. The resulting specificity and
sensitivity curves as a function of fERG decay threshold at 1
and 3 years from baseline are shown in Figure 10A (continuous
lines). The corresponding ROC curves for 1- and 3-year follow-
up are shown in Figure 10B. The area under the ROC curve—
commonly used as a measure of test accuracy23—is 0.74 at 1
year (0.69–0.79, fifth to 95th percentiles) and 0.825 at 3 years
(0.77–0.87, fifth to 95th percentiles). The fifth to 95th
percentile intervals indicated are obtained by running 10,000
bootstrap simulations for each data set (1 and 3 years),
computing the area under the ROC curve for each simulation
and the overall distribution of the latter from all the simulations
of each data set (Fig. 10C).
DISCUSSION
This retrospective study shows that fERG follow-up leads to a
clear-cut subdivision of CRD patients in stationary or decaying,
providing quantitative criteria defining each typology. Station-
ary patients had fERG amplitudes that remained either above 1
lV or below 0.5 lV, with a few occasional exceptions.
Decaying patients had either a slow (7%–10% annual loss) or
a fast (28%–39% annual loss) decaying fERG, spanning in time
from above 1 lV to below 0.5 lV. Baseline age did not
significantly differ between high-stationary, fast-, and slow-
decaying patients, suggesting that these different fERG time
FIGURE 8. Examples of fERG and BCVA decline in individual CRD eyes.
Solid squares are fERG data; open circles are BCVA data. Top:
Concomitant onset of fERG and BCVA decline from baseline. Bottom:
BCVA decline onset several years after fERG decline onset. Measures
are normalized to baseline to show their relative decline. BCVA is
quantified as MAR. fERG data are reported only when corresponding
BCVA measures existed. For each case, baseline BCVA is indicated in
decimal.
FIGURE 9. BCVA survival probability as a function of time after first
fERG loss from baseline in progressive CRD patients. The upper curve
is the time between first fERG loss from baseline and first BCVA loss,
the lower curve is the maximum time BCVA stayed constant after first
fERG drop. The two curves represent an upper and a lower bound,
respectively, for BCVA survival probability. This analysis is based on N¼
32 eyes, 17 patients. Patients with baseline BCVA <0.1 decimal were
not included, as they were considered already at the minimum BCVA
reliably detectable by Snellen.
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courses reflect different phenotypes and not just different
stages of the disease.
The subdivision of CRD forms into stationary and progres-
sive is consistent with the standard categorization based on
subjective symptoms and clinical signs recorded with a variety
of techniques.1,2,4 The existence of fast- and slow-progressing
CRD forms has been reported in previous studies, although
few diagnostic measures until now provided a clear-cut
separation of the two. Microperimetric studies document fast
and slow progression rates for the increase of cone relative
threshold over time,12 and for the sensitivity at the lesion
border24 in CRD patients. Similarly, fast and slow progression
rates have been reported for the enlargement of the central
scotoma in CRD.25 Of interest, the range of decay rates found
with fERG follow-up overlaps with the range of decay rates
identified in previous studies.12,14,24,25 This finding suggests
that, with different degrees of sensitivity and reliability, fERG
parallels other techniques in detecting the progression of
common biological processes underlying central retinal
dysfunction in CRD.
fERG and Visual Acuity Progression
Best-corrected visual acuity is a measure of central retina
functionality of enormous impact on a patient’s daily life. For
this reason, we analyzed how fERG follow-up compared with
BCVA time course in terms of reliability, effectiveness, and early
detection of individual risk of visual decay in CRD patients.
We found that fERG discriminates stationary and progres-
sive CRD forms in agreement with BCVA follow-up: patients
with stationary fERG experienced very limited acuity loss with
time, while patients with decaying fERG experienced signifi-
cant BCVA decline with time. Moreover, we found that BCVA
losses in decaying patients were always accompanied by fERG
amplitude losses. The reverse was not true, as fERG losses
could anticipate BCVA losses. Indeed, BCVA could survive
several years after the first fERG loss, although it eventually
decayed.
Taken together, these results demonstrate that fERG follow-
up offers high diagnostic reliability and a precocious sensitivity
to disease progression that always detects acuity losses and can
often anticipate them for several years.
Accuracy of fERG Follow-up for Early Decay
Detection
The fERG repeatability cutoff range defined a priori on the
basis of intravisit variability was comparable with that reported
for psychophysical techniques in CRD with known geno-
type.10,26 However, the stereotyped behavior of fERG curves
allowed an a posteriori analysis of the data set to obtain more
realistic cutoff criteria and determine the accuracy of the test.
This analysis showed that threshold for fERG decay detection
can be lowered considerably with respect to the initial
conservative cutoff. This same analysis, combined with
bootstrap, produced ROC curves that can be used to estimate
the accuracy of fERG follow-up in determining whether
patients are stationary or decaying. The resulting areas under
the ROC curve—0.74 at 1 year and 0.825 at 3 years—place the
test in the high-accuracy ranks according to standard
classification.23
CONCLUSIONS: PRO AND CONTRA OF fERG
To our knowledge, no other study has employed the long-term
follow-up of central retina ERG recordings to longitudinally
evaluate the functional decline in CRD patients. Here, we
showed that fERG represents a direct and sensitive assay to
detect, categorize, and follow the progression of central retinal
dysfunction in CRD. This approach may help anticipate, for an
individual patient, the likelihood and rate of further disease
progression before visual acuity loss has occurred.
Macular focal cone ERG follow-up cannot replace any of the
presently available diagnostic techniques for CRD: it lacks the
fine spatial details detectable with multifocal ERG27 and
microperimetry,10 has no clear relation to real life as visual
acuity does, nor the diagnostic sensitivity of eye imaging.15 Yet,
its reliable, clear-cut, and precocious determination of individ-
ual patient risk of decay strongly commends its inclusion
among the primary diagnostic tools for CRD.
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FIGURE 10. Receiver-operator characteristic (ROC) curves for fERG decay detection test. (A) Specificity and sensitivity as a function of the
minimum fERG loss chosen to indicate a true decay (cutoff threshold) at 1 and 3 years from baseline, as derived from a posteriori data set analysis (1
year, continuous black line; 3 years, continuous gray line). Dashed line is the specificity derived a priori from intervisit variability. (B) ROC curves
for fERG decay test at 1 and 3 years from baseline. (C) Mean and distribution of the area under the ROC curves obtained from bootstrap analysis at 1
year (black) and 3 years (gray) from baseline.
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